Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women (scientific article published on January 2015)

Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding

Q30679524

Effect of early versus deferred antiretroviral therapy for HIV on survival

Q33789114

Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial

Q33863552

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts

Q34116017

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

Q34216455

Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana

Q34306176

Antiretroviral regimens in pregnancy and breast-feeding in Botswana

Q34395082

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa

Q34431819

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting

Q34778123

Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy

Q34814795

Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women

Q34974794

Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy

Q35551457

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

Q35691909

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission

Q36231035

Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial

Q36866309

Protease inhibitor levels in hair strongly predict virologic response to treatment

Q37124640

Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry

Q37159364

Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis

Q37335159

Class-sparing regimens for initial treatment of HIV-1 infection

Q37454026

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda

Q37600844

Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child

Q38112591

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

Q38967453

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

Q40082978

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study

Q43281055

Reduced lopinavir exposure during pregnancy

Q46112061

Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected Mothers

Q56762683

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study

Q77754217

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

Uganda

lopinavir

ritonavir

efavirenz

lopinavir/ritonavir

anti-retroviral agent

Q50430310

P304

page(s)

183-191

P577

publication date

2015-01-01

P1433

published in

AIDS

Q4651863

P1476

title

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women

P478

volume

Reverse relations

cites work (P2860)

Q30381808	A Systematic Review of Interventions to Reduce Maternal Mortality among HIV-Infected Pregnant and Postpartum Women
Q59802846	Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: progress, gaps and research needs
Q39234019	Advances in therapy for the prevention of HIV transmission from mother to child
Q59128516	Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study
Q95643468	Anemia and Micronutrient Status during Pregnancy, and Their Associations with Obstetric and Infant Outcomes among HIV-Infected Ugandan Women Receiving Antiretroviral Therapy
Q36576508	Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women
Q90074397	Brief Report: Markers of Spontaneous Preterm Delivery in Women Living With HIV: Relationship With Protease Inhibitors and Vitamin D
Q38961883	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Q47724822	Development and Validation of an Assay to Analyze Atazanavir in Human Hair Via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Q92535721	Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
Q45324863	Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy
Q28070420	HIV-free survival at 12-24 months in breastfed infants of HIV-infected women on antiretroviral treatment
Q35627832	Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women
Q36439051	No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects
Q55311524	Novel methods to estimate antiretroviral adherence: protocol for a longitudinal study.
Q96647298	Obstetric Management of COVID-19 in Pregnant Women
Q36395153	Paediatric HIV: Progress on Prevention, Treatment and Cure
Q92430407	Pregnancy outcome among HIV-infected women on different antiretroviral therapies in Ethiopia: a cohort study
Q57070417	Pregnancy outcomes in the era of universal antiretroviral treatment in sub-Saharan Africa (POISE Study)
Q48569593	Prevention of Hiv-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in Hiv-1-Infected Women with High Cd4 Cell Count (Impaact Promise): A R
Q33657188	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3.
Q36167659	Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective Study
Q38852269	Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda
Q48521585	What is new in perinatal HIV prevention?